FOR IMMEDIATE RELEASE

Octapharma Introduces cutaquig® & IgCares™, Sponsors IDF National Conference

Patient Support Program Launched with New Therapy Provides Sustainability Initiative, Donations for PI Charities and Educational Resources

HOBOKEN, N.J. (June 27, 2019) – Octapharma USA sponsored the recently completed Immune Deficiency Foundation (IDF) National Conference and sponsored a symposium after the event, introducing its newest product, cutaquig® (Immune Globulin Subcutaneous (Human) - hipp), a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults.

Octapharma simultaneously launched its free IgCares™ program, an initiative managed through the community portal at www.IgCares.com providing:

- A safety and sustainability service that transforms medical waste into energy;
- Octapharma donations to PI non-profit organizations;
- Access to educational and informational resources for PI patients; and
- Personal connections to peers, the PI community, and patient advocates.

“Multiple clinical trials have demonstrated the safety and efficacy of cutaquig® in treating PI in adults so we are pleased to introduce the product,”¹ ² said Octapharma USA President Flemming Nielsen. “We are excited to launch IgCares™ as well because it provides cutaquig® patients with benefits through educational and community resources as well as support for patient organizations and the environment.”

“We are delighted that people with primary immunodeficiency diseases who rely upon lifesaving immunoglobulin replacement therapy have a new subcutaneous option in cutaquig®,” said IDF President & CEO John G. Boyle. “And we congratulate Octapharma on their launch of IgCares™ as a program to help the PI community. Programs that support both members of our community and the organizations trying to improve their quality of life is a win-win all around.”

Patients will receive a custom sharps container for needles and other medical waste and an additional box for product shipping materials with their monthly infusion shipment of cutaquig®. The IgCares™ program enables patients to return product materials at no cost, keeping the medical waste out of landfills.

“The IgCares™ initiative helps protect the environment by transforming medical waste into energy,” Nielsen added. “Everything patients return will be repurposed into an industrial material used to generate electricity for homes and businesses.”
This IgCares™ initiative lets patients access educational and informational resources at www.IgCares.com, including a wide range of tips, tactics, and tools to succeed in the patient treatment journey. The IgCares™ portal also connects patients with peers, the PI community, and patient advocates who are available to answer questions.

Patients earn points through IgCares™ every time they fill a prescription, complete educational activities, track their treatment and participate in the sustainability program. Patients can convert their points into a charitable donation by Octapharma made to one of four PI community organizations, including the IDF, Jeffrey Modell Foundation, Foundation for Primary Immunodeficiency Diseases and International Patient Organisation for Primary Immunodeficiencies.

Cutaquig® is available through four distribution partners, including Healix, KabaFusion, Main Bridge Health Partners and NuFactor.

**About cutaquig®**

Cutaquig® (Immune Globulin Subcutaneous (Human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults.

**WARNING: THROMBOSIS**

- Thrombosis may occur with immune globulin products, including cutaquig®. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

- For patients at risk of thrombosis, administer cutaquig® at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Please see full prescribing information for complete boxed warning and other important information at www.cutaquigus.com.

**About the Octapharma Group**

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 8,314 people worldwide to support the treatment of patients in over 115 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.
REFERENCES
1. Efficacy, Safety and Tolerability of a Subcutaneous Human Immunoglobulin 16.5% (cutaquig®) in Adult Patients with Primary Immune Deficiencies. Latyshev E. et al. Poster presented at: Clinical Immunology Society Annual Meeting; April 4, 2019, Atlanta, GA.


MEDIA CONTACT:
Anita Callari
Yankee Public Relations
anita@yankeepr.com
908-425-4878

CUTA-0148

Octapharma USA, Inc. • 121 River Street, Suite 1201 • Hoboken, NJ 07030 • 201-604-1130 • www.octapharmausa.com